...Preclin Kinases/Transcription factors p38 mitogen-activated protein kinase (p38 MAPK; MAPK14) Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) / EIP Pharma LLC...

...CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million on May 16 in a series B round...
...expressed in the microglia and astrocytes where it regulates inflammation. EIP Pharma LLC, Cambridge, Mass. Elizabeth S. Eaton neflamapimod (VX-745) EIP Pharma LLC p38...

...CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million in a series B round led by new...
...MAPK14), which is expressed in the microglia and astrocytes where it regulates inflammation. Elizabeth S. Eaton neflamapimod (VX-745) EIP Pharma LLC p38...

...previously tested by Astellas to treat pain, but Cardeus is exploring other indications including neurodegeneration. EIP Pharma LLC...
...Therapeutics Ltd. London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cardeus Pharmaceuticals Inc., Menlo Park, Calif. EIP Pharma LLC...

...mg dose of neflamapimod in a Phase IIb trial. The company licensed neflamapimod from Vertex. EIP Pharma LLC...
...Learning Test-Revised (HLVT-R), Mini-Mental State Examination (MMSE) and safety Status: Phase IIa data Milestone: NA Julian Zhu neflamapimod VX-745 EIP Pharma LLC Vertex...

...mg dose of neflamapimod in a Phase IIb trial. The company licensed neflamapimod from Vertex. EIP Pharma LLC...
...Memory Scale (WMS), Mini-Mental State Examination (MMSE) and safety Status: Phase IIa data Milestone: NA Julian Zhu neflamapimod VX-745 EIP Pharma LLC Vertex...

...two from AC Immune S.A. , for which Phase I data are expected in 1H17. EIP Pharma LLC...
...but not for AD. Inflammation is believed to be a downstream affect of plaque formation. EIP Pharma...
...St. Louis, Mo. Columbia University, New York, N.Y. Columbia University Medical Center, New York, N.Y. EIP Pharma LLC...